8 Paul Tudor Jones II Astrazeneca plc Trades
Paul Tudor Jones II's position in Astrazeneca plc is currently worth $2.16 Million. That's 0.03% of their equity portfolio (664th largest holding). The first Astrazeneca plc trade was made in Q2 2014. Since then Paul Tudor Jones II bought shares three more times and sold shares on four occasions. The investor's estimated purchase price is $2.24 Million, resulting in a loss of 3.7%.
News about Astrazeneca plc - ADR and Paul Tudor Jones II
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for th...
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining ...
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based ...
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from th...